<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432467</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_MSC(Fertility)</org_study_id>
    <nct_id>NCT04432467</nct_id>
  </id_info>
  <brief_title>Fertility Restoration Using Autologous Mesenchymal Stem Cells</brief_title>
  <official_title>Fertility Restoration Using Autologous Adipose Tissue Derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian Medical Academy of Post-Graduate Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of the patients with scarring and adhesions in the uterus resulting from caesarean
      section or chronic inflammation in the mucosa of the uterus and fallopian tubes and
      preventing the occurrence of these effects in the future
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the project is to develop a biomedical cell product based on autologous adipose
      tissue derived mesenchymal stem cells and a biodegradable carrier for highly effective
      treatment and prevention of scarring and adhesions in the uterus acquired as a result of
      cesarean section or chronic inflammatory processes in the uterine mucosa and fallopian tubes;
      to conduct the clinical trials of the biomedical cell product in the treatment of uterus
      scarring and infertility in women.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cured patients</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients cured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>MSC application related adverse events assessed by blood count, liver and function tests</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Endometritis</condition>
  <condition>Uterus; Scar</condition>
  <condition>Uterine Synechiae</condition>
  <condition>Fallopian Tube Obstruction</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells</intervention_name>
    <description>Autologous adipose tissue-derived mesenchymal stem cells</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard treatment</intervention_name>
    <description>standard treatment according to clinical protocols</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic endometritis

          -  postoperative uterus scars

          -  uterine synechia

          -  fallopian tube obstruction

          -  absence of acute inflammation in the uterus

        Exclusion Criteria:

          -  Patients with genetic diseases of muscle and connective tissue;

          -  Patients with malformations of the uterus;

          -  Acute and chronic infectious diseases: HIV, mycoplasma infection, hepatitis B and C,
             syphilis; autoimmune diseases; oncological diseases; continuous hormonal therapy with
             cytostatics corticosteroids; acute noncommunicable diseases;

          -  mental disorders;

          -  Drug or alcohol addiction;

          -  Benign tumors of uterus and appendages;

          -  Hypersensitivity to any component of the studied biomedical cell product.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor D Volotovski, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Head of the Lab of Institute of Biophysics and Cell Engineering</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrei Y Hancharou, MD, PHD</last_name>
    <phone>+375296248972</phone>
    <email>hancharou@ibp.org.by</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna G Poleshko, Dr</last_name>
    <phone>+375295105774</phone>
    <email>renovacio888@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrei Y Hancharou, Dr</last_name>
      <phone>375296248972</phone>
      <email>andrei.hancharou@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna G Poleshko, Dr</last_name>
      <phone>+375295105774</phone>
      <email>renovacio888@yandex.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fertility restoration</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
    <mesh_term>Gynatresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

